70-year-old-woman with extremely dense breasts

70-year-old-woman with extremely dense breasts. A. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from baseline AB-MR examination is negative (BI-RADS category 1). B. Axial subtracted contrast-enhanced fat-suppressed T1-weighted image from subsequent-round AB-MR examination performed 2 years later shows new 5-mm enhancing mass in upper outer right breast (arrow), which was not seen on mammogram performed 5 months prior. Examination was assessed as BI-RADS category 5. Ultrasound-guided core biopsy yielded invasive ductal carcinoma (ER+/PR+/HER2-).


June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower abnormal interpretation rate (AIR) compared to baseline examinations, while maintaining high cancer detection rate (CDR), according to the American Journal of Roentgenology (AJR).

Pointing out that all cancers detected by subsequent-round examinations were early-stage node-negative cancers, “further investigations are warranted to optimize the screening interval,” noted first author Christine E. Edmonds, MD, from the Hospital of the University of Pennsylvania. “The findings support sequential AB-MR for supplemental screening in individuals with dense breasts.”

AJR Editor in Chief Andrew Rosenkrantz, MD, speaks with Dr. Edmonds about her study comparing outcomes between baseline and subsequent rounds of screening abbreviated breast MRI in individuals with dense breasts.

Edmonds et al.’s AJR accepted manuscript included patients with dense breasts, at otherwise average breast-cancer risk, who underwent AB-MR for supplemental screening between December 20, 2016 and May 10, 2023. After extracting clinical interpretations and results of recommended biopsies for AB-MR examinations from the EMR, the researchers compared baseline and subsequent-round AB-MR examinations.

Ultimately, in women with dense breasts, subsequent-round AB-MR for supplemental screening achieved lower AIR versus baseline rounds (7.8% vs. 17.4%, p <.001), while maintaining high CDR (12.1 vs. 18.9 per 1000, p =.37). All cancers diagnosed by subsequent round AB-MR were stage 0 or 1; had size of 0.3-1.2 cm; and exhibited node-negative status.

For more information: www.arrs.org


Related Content

News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now